© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
September 21, 2022
Before closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.
September 15, 2022
Expert perspectives on the utilization of genomic profiling in patients with metastatic castration-sensitive prostate cancer to impact treatment decisions.
September 14, 2022
A brief discussion on the use of doublet versus triplet therapy in patients with low-volume metastatic prostate cancer.
September 08, 2022
Expert panelists consider which factors would push them toward utilizing triplet therapy in patients with metastatic castration-sensitive prostate cancer.
Centering discussion on a patient case of high-volume metastatic CSPC, expert panelists review the option of triplet therapy based on the PEACE-1 trial.
September 01, 2022
Shared insight on optimal patient monitoring strategies while administering therapy for metastatic castration-sensitive prostate cancer.
August 24, 2022
Panelists provide comprehensive insight on treatment strategies specific to the setting of low-volume metastatic prostate cancer.
Expert oncologists review the selection of apalutamide + androgen deprivation therapy in this patient scenario of metastatic castration-sensitive prostate cancer.
August 18, 2022
A brief discussion on the toxicities and drug-drug interactions associated with frontline therapies in metastatic CSPC and when it would be appropriate to alter treatment to mitigate toxicity.